| abstract |
The present invention relates to nanoparticles for immunotherapy and to a pharmaceutical composition comprising NK cells and the nanoparticles. According to one aspect, by means of the nanoparticles, a gene can be delivered to and expressed in immune cells, and the NK cells having the nanoparticles incorporated therein can effectively treat cancer without adverse side effects of existing CAR T cells and enable cell tracking at the same time. |